IQV
Price
$274.48Alerts
Change
-$0.67 (-0.24%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
44.74B
91 days until earnings call
Intraday BUY SELL Signals
IRIX
Price
$0.68Alerts
Change
-$0.02 (-2.86%)
Updated
Nov 11 closing price
Capitalization
11.7M
5 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IQV vs IRIX

IQV vs IRIX Comparison Chart in %
View a ticker or compare two or three
VS
IQV vs. IRIX commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IQV is a Hold and IRIX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IQV with price predictions
Nov 11, 2026

IQV in upward trend: price rose above 50-day moving average on November 06, 2026

IQV moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 21 of 28 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for IQV just turned positive on November 10, 2026. Looking at past instances where IQV's MACD turned positive, the stock continued to rise in 26 of 41 cases over the following month. The odds of a continued upward trend are 63%.

Following a +5.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where IQV advanced for three days, in 186 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IQV as a result. In 56 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

IQV broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. IQV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.251) is normal, around the industry mean (67.298). P/E Ratio (33.477) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.985) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.693) is also within normal values, averaging (9.775).

The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

A.I.Advisor
a Summary for IRIX with price predictions
Nov 11, 2026

IRIX in downward trend: 10-day moving average broke below 50-day moving average on November 06, 2026

The 10-day moving average for IRIX crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for IRIX moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRIX as a result. In 74 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.

The Moving Average Convergence Divergence Histogram (MACD) for IRIX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 33 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

IRIX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 67 cases where IRIX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

Following a +1.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRIX advanced for three days, in 151 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

IRIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 84 of 112 cases where IRIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.955) is normal, around the industry mean (4.142). P/E Ratio (-3.330) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (3.870) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.204) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. IRIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
IQV vs IRIX: Fundamental Ratings
IQV
IRIX
OUTLOOK RATING
1..100
2750
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
43100
PRICE GROWTH RATING
1..100
1178
P/E GROWTH RATING
1..100
2715
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IRIX's Valuation (73) in the Medical Specialties industry is in the same range as IQV (77) in the Servicestothe Health Industry industry. This means that IRIX’s stock grew similarly to IQV’s over the last 12 months.

IQV's Profit vs Risk Rating (86) in the Servicestothe Health Industry industry is in the same range as IRIX (100) in the Medical Specialties industry. This means that IQV’s stock grew similarly to IRIX’s over the last 12 months.

IQV's SMR Rating (43) in the Servicestothe Health Industry industry is somewhat better than the same rating for IRIX (100) in the Medical Specialties industry. This means that IQV’s stock grew somewhat faster than IRIX’s over the last 12 months.

IQV's Price Growth Rating (11) in the Servicestothe Health Industry industry is significantly better than the same rating for IRIX (78) in the Medical Specialties industry. This means that IQV’s stock grew significantly faster than IRIX’s over the last 12 months.

IRIX's P/E Growth Rating (15) in the Medical Specialties industry is in the same range as IQV (27) in the Servicestothe Health Industry industry. This means that IRIX’s stock grew similarly to IQV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IQVIRIX
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
63%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
63%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
67%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 15 days ago
74%
Declines
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 1 day ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
61%
Bullish Trend 1 day ago
78%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
75%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (IQV: $274.53 vs. IRIX: $0.68)
Brand notoriety: IQV: Notable vs. IRIX: Not notable
IQV represents the Medical Specialties, while IRIX is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: IQV: 92% vs. IRIX: 24%
Market capitalization -- IQV: $44.74B vs. IRIX: $11.7M
IQV [@Medical Specialties] is valued at $44.74B. IRIX’s [@Medical/Nursing Services] market capitalization is $11.7M. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $190.22B. The average market capitalization across the [@Medical Specialties] industry is $20.94B. The average market capitalization across the [@Medical/Nursing Services] industry is $6.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IQV’s FA Score shows that 2 FA rating(s) are green while IRIX’s FA Score has 1 green FA rating(s).

  • IQV’s FA Score: 2 green, 3 red.
  • IRIX’s FA Score: 1 green, 4 red.
According to our system of comparison, IQV is a better buy in the long-term than IRIX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IQV’s TA Score shows that 3 TA indicator(s) are bullish while IRIX’s TA Score has 4 bullish TA indicator(s).

  • IQV’s TA Score: 3 bullish, 4 bearish.
  • IRIX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, IQV is a better buy in the short-term than IRIX.

Price Growth

IQV (@Medical Specialties) experienced а +4.07% price change this week, while IRIX (@Medical/Nursing Services) price change was -4.34% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.83%. For the same industry, the average monthly price growth was -5.05%, and the average quarterly price growth was +38.36%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.76%. For the same industry, the average monthly price growth was -4.63%, and the average quarterly price growth was -1.72%.

Reported Earning Dates

IQV is expected to report earnings on Feb 11, 2027.

IRIX is expected to report earnings on Nov 17, 2026.

Industries' Descriptions

@Medical Specialties (-4.83% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

@Medical/Nursing Services (-2.76% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

IQV and

Correlation & Price change

A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IQV
1D Price
Change %
IQV100%
-0.23%
CRL - IQV
71%
Closely correlated
-0.90%
TMO - IQV
67%
Closely correlated
-0.07%
RVTY - IQV
59%
Loosely correlated
-0.53%
A - IQV
58%
Loosely correlated
-0.52%
ICLR - IQV
54%
Loosely correlated
-2.41%
More

IRIX and

Correlation & Price change

A.I.dvisor tells us that IRIX and NTRA have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IRIX and NTRA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IRIX
1D Price
Change %
IRIX100%
-2.30%
NTRA - IRIX
30%
Poorly correlated
+2.51%
NEO - IRIX
27%
Poorly correlated
-0.77%
IQV - IRIX
27%
Poorly correlated
-0.23%
MDXH - IRIX
26%
Poorly correlated
+5.17%
DRIO - IRIX
26%
Poorly correlated
-11.09%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PBM3.180.15
+4.95%
Psyence Biomedical Ltd.
IVVD0.600.02
+4.33%
Invivyd
MDU19.440.16
+0.83%
MDU Resources Group
WTW334.181.31
+0.39%
Willis Towers Watson Public Limited
IBCP36.740.10
+0.27%
Independent Bank Corp